JS207 combination therapy for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new combination treatment for people with advanced triple-negative breast cancer who have not yet received treatment for their advanced disease. It aims to see if the combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic triple-negative breast cancer (no HER2, ER, or PR markers).
- You have not had any prior cancer treatment for advanced or metastatic disease.
- If you had chemotherapy before surgery, you must have had a 6-month or longer break before cancer returned.
- You are in good overall health with adequate organ function and an ECOG performance status of 0 or 1 (able to carry out daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called JS212, given alone or with other medicines, for people with advanced triple-negative breast cancer that has not spread too much before. It aims to see if the drug can shrink tumors or slow the disease.
This study tests a new drug called JSKN016 against standard chemotherapy options for triple-negative breast cancer that has stopped responding to previous treatments. The trial aims to find out if JSKN016 works better or offers other benefits for patients like you.
This trial tests a new drug, 9MW2821 (sometimes with a PD-1 inhibitor), for people with advanced triple-negative breast cancer. It may be an option if you've already tried standard treatments or haven't started any yet.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This study compares a new drug (JS004) added to an immunotherapy and chemotherapy combination versus the usual immunotherapy plus chemotherapy or chemotherapy alone. It aims to see if adding this new drug can shrink breast cancer more effectively before surgery.
This trial tests a new drug, JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow. It's for people with nasopharyngeal cancer that has not spread too much, and who have not had certain prior treatments.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.